Home/Pipeline/LumaGEM for Diagnostic Work-up

LumaGEM for Diagnostic Work-up

Equivocal Breast Imaging Findings

CommercialActive

Key Facts

Indication
Equivocal Breast Imaging Findings
Phase
Commercial
Status
Active
Company

About CMR Naviscan

CMR Naviscan, a unit of the larger CMR corporation, is a commercial-stage medical device company specializing in molecular breast imaging. Its core product, the LumaGEM MBI system, addresses a critical gap in breast cancer screening for the approximately 40-50% of women with dense breast tissue, where mammography is less effective. The company's value proposition is built on clinical data showing increased invasive cancer detection rates and a reduction in unnecessary biopsies, leading to proven healthcare savings. Operating as a private entity, it leverages over 40 years of parent company expertise in diagnostic imaging to market its FDA-registered systems.

View full company profile

Therapeutic Areas